Sulfentanil
PreclinicalSmall molecule
Sulfentanil is one of 18 small molecule programs targeting Strabismus. It is currently in Preclinical.
1
Indications
2
Total Trials
2
Active Trials
17
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
24 competitors in Strabismus
#DrugCompanyPhaseTrials
1Botox
RRevance Therapeutics, Inc.
Approved
Versed
CConrado Roberto Hoffmann Filho
Approved
Tylenol
KKenvue Brands
Approved
Ketalar
AAultman Health Foundation
Approved
Aloxi
AAvyxa
Approved
Decadron
AAspen Global Incorporated
Approved
Botulinum Toxin a
GSKPhase 3
Dilaudid
RRhodes Pharmaceuticals, L.P.
Preclinical
Duragesic
CCephalon
Preclinical
Esmeron
FFresenius Kabi USA, LLC
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Sulfentanil. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details